FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203483887> ?p ?o ?g. }

• W3203483887 endingPage "662" @default.
• W3203483887 startingPage "654" @default.
• W3203483887 abstract "Previous studies have shown that the addition of carboplatin to neoadjuvant chemotherapy improved the pathologic complete response (pCR) rate in patients suffering from triple-negative breast cancer (TNBC) and patients who obtained a pCR could achieve prolonged event-free survival (EFS) and overall survival (OS). However, no studies have assessed the effects of the combination of docetaxel and carboplatin without anthracycline with taxane-based and anthracycline-based regimens. The NeoCART study was designed as a multicenter, randomized controlled, open-label, phase II trial to assess the efficacy and safety of docetaxel combined with carboplatin in untreated stage II-III TNBC. All eligible patients were randomly assigned, at a 1:1 ratio, to an experimental docetaxel plus carboplatin (DCb) for six cycles group (DCb group) or an epirubicin plus cyclophosphamide for four cycles followed by docetaxel for four cycles group (EC-D group). PCR (ypT0/is ypN0) was evaluated as the primary outcome. Between 1 September 2016 and 31 December 2019, 93 patients were randomly assigned and 88 patients were evaluated for the primary endpoint (44 patients in each group). In the primary endpoint analysis, 27 patients in the DCb group (61.4%, 95% CI 47.0-75.8) and 17 patients in the EC-D group achieved a pCR (38.6%, 95% CI 24.3-53.0; odds ratio 2.52, 95% CI 2.4-43.1; Pnoninferiority = .004). Noninferiority was met, and the DCb regimen was confirmed to be superior to the EC-D regimen (P = .044, superiority margin of 5%). At the end of the 37-month median follow-up period, OS and EFS rates were equivalent in both groups." @default.
• W3203483887 created "2021-10-11" @default.
• W3203483887 creator A5003459470 @default.
• W3203483887 creator A5020631350 @default.
• W3203483887 creator A5033544481 @default.
• W3203483887 creator A5034083482 @default.
• W3203483887 creator A5034733312 @default.
• W3203483887 creator A5036761448 @default.
• W3203483887 creator A5039729883 @default.
• W3203483887 creator A5045873809 @default.
• W3203483887 creator A5052217154 @default.
• W3203483887 creator A5052594077 @default.
• W3203483887 creator A5060120199 @default.
• W3203483887 creator A5068190515 @default.
• W3203483887 creator A5068252474 @default.
• W3203483887 creator A5084018016 @default.
• W3203483887 creator A5088880132 @default.
• W3203483887 date "2021-10-07" @default.
• W3203483887 modified "2023-10-17" @default.
• W3203483887 title "Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in <scp>triple‐negative</scp> , <scp>early‐stage</scp> breast cancer ( <scp>NeoCART</scp> ): Results from a multicenter, randomized controlled, <scp>open‐label</scp> phase <scp>II</scp> trial" @default.
• W3203483887 cites W2075894019 @default.
• W3203483887 cites W2086064725 @default.
• W3203483887 cites W2096745115 @default.
• W3203483887 cites W2101760255 @default.
• W3203483887 cites W2109997465 @default.
• W3203483887 cites W2110645520 @default.
• W3203483887 cites W2114397636 @default.
• W3203483887 cites W2118605519 @default.
• W3203483887 cites W2119549339 @default.
• W3203483887 cites W2127227293 @default.
• W3203483887 cites W2142486051 @default.
• W3203483887 cites W2157285286 @default.
• W3203483887 cites W2170602872 @default.
• W3203483887 cites W2291541708 @default.
• W3203483887 cites W2434209561 @default.
• W3203483887 cites W2618058692 @default.
• W3203483887 cites W2734897937 @default.
• W3203483887 cites W2788106879 @default.
• W3203483887 cites W2804692318 @default.
• W3203483887 cites W2903044532 @default.
• W3203483887 cites W2913286462 @default.
• W3203483887 cites W3011708355 @default.
• W3203483887 cites W3089768241 @default.
• W3203483887 cites W3098994343 @default.
• W3203483887 cites W4230873417 @default.
• W3203483887 doi "https://doi.org/10.1002/ijc.33830" @default.
• W3203483887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34591977" @default.
• W3203483887 hasPublicationYear "2021" @default.
• W3203483887 type Work @default.
• W3203483887 sameAs 3203483887 @default.
• W3203483887 citedByCount "15" @default.
• W3203483887 countsByYear W32034838872022 @default.
• W3203483887 countsByYear W32034838872023 @default.
• W3203483887 crossrefType "journal-article" @default.
• W3203483887 hasAuthorship W3203483887A5003459470 @default.
• W3203483887 hasAuthorship W3203483887A5020631350 @default.
• W3203483887 hasAuthorship W3203483887A5033544481 @default.
• W3203483887 hasAuthorship W3203483887A5034083482 @default.
• W3203483887 hasAuthorship W3203483887A5034733312 @default.
• W3203483887 hasAuthorship W3203483887A5036761448 @default.
• W3203483887 hasAuthorship W3203483887A5039729883 @default.
• W3203483887 hasAuthorship W3203483887A5045873809 @default.
• W3203483887 hasAuthorship W3203483887A5052217154 @default.
• W3203483887 hasAuthorship W3203483887A5052594077 @default.
• W3203483887 hasAuthorship W3203483887A5060120199 @default.
• W3203483887 hasAuthorship W3203483887A5068190515 @default.
• W3203483887 hasAuthorship W3203483887A5068252474 @default.
• W3203483887 hasAuthorship W3203483887A5084018016 @default.
• W3203483887 hasAuthorship W3203483887A5088880132 @default.
• W3203483887 hasConcept C121608353 @default.
• W3203483887 hasConcept C126322002 @default.
• W3203483887 hasConcept C141071460 @default.
• W3203483887 hasConcept C143998085 @default.
• W3203483887 hasConcept C168563851 @default.
• W3203483887 hasConcept C203092338 @default.
• W3203483887 hasConcept C2776694085 @default.
• W3203483887 hasConcept C2776755627 @default.
• W3203483887 hasConcept C2776802502 @default.
• W3203483887 hasConcept C2777511904 @default.
• W3203483887 hasConcept C2778239845 @default.
• W3203483887 hasConcept C2780110267 @default.
• W3203483887 hasConcept C2780835546 @default.
• W3203483887 hasConcept C2781190966 @default.
• W3203483887 hasConcept C2781413609 @default.
• W3203483887 hasConcept C2781451048 @default.
• W3203483887 hasConcept C530470458 @default.
• W3203483887 hasConcept C71924100 @default.
• W3203483887 hasConceptScore W3203483887C121608353 @default.
• W3203483887 hasConceptScore W3203483887C126322002 @default.
• W3203483887 hasConceptScore W3203483887C141071460 @default.
• W3203483887 hasConceptScore W3203483887C143998085 @default.
• W3203483887 hasConceptScore W3203483887C168563851 @default.
• W3203483887 hasConceptScore W3203483887C203092338 @default.
• W3203483887 hasConceptScore W3203483887C2776694085 @default.
• W3203483887 hasConceptScore W3203483887C2776755627 @default.
• W3203483887 hasConceptScore W3203483887C2776802502 @default.
• W3203483887 hasConceptScore W3203483887C2777511904 @default.
• W3203483887 hasConceptScore W3203483887C2778239845 @default.

• next